AI drug discovery platform Insilico Medicine announces $255 million in Series C funding
TechCrunch
JUNE 22, 2021
Insilico Medicine is a Hong Kong-based company founded in 2014 around one central premise: that AI-assisted systems can identify novel drug targets for untreated diseases, assist in the development of new treatments and eventually predict how well those treatments may perform in clinical trials. Previously, the company had raised $51.3
Let's personalize your content